New ablative techniques can eradicate dysplastic Barrett oesophagus more effectively, but require longer-term follow-up to strengthen their evidence base
Barrett oesophagus is a precursor lesion that can progress to oesophageal adenocarcinoma. Barrett oesophagus affects about 1% of the population and is believed to be due to chronic gastro-oesophageal reflux disease.1 Patients with Barrett oesophagus have a 30–40-fold relative risk of developing oesophageal adenocarcinoma, which usually occurs via progression through low-grade dysplasia (LGD) to high-grade dysplasia (HGD).2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.